Neuro-oncology advances
Mouse models of glioblastoma for the evaluation of novel therapeutic strategies.
Neuro-oncology advances
Generation of immunocompetent syngeneic allograft mouse models for pediatric diffuse midline glioma.
Neuro-oncology advances
TERT promotor status does not add prognostic information in IDH-wildtype glioblastomas fulfilling other diagnostic WHO criteria: A report of the RANO resect group.
Neuro-oncology advances
CDKN2A/B co-deletion is associated with increased risk of local and distant intracranial recurrence after surgical resection of brain metastases.
Neuro-oncology advances
Quantitative analysis of MGMT promoter methylation in glioblastoma suggests nonlinear prognostic effect.
Neuro-oncology advances
Level I and II deficits-A clinical survey on international practice of awake craniotomy and definitions of postoperative "major" and "minor" deficits.
Neuro-oncology advances
Longitudinal profiling of IDH-mutant astrocytomas reveals acquired RAS-MAPK pathway mutations associated with inferior survival.
Neuro-oncology advances